Intestinal voltage-gated calcium channel (Intestinal VGCC)

Intestinal voltage-gated calcium channels (VGCCs) are critical membrane proteins that regulate gastrointestinal motility and sensory signaling by mediating the influx of calcium ions into excitable cells, such as smooth muscle cells and interstitial cells of Cajal (ICCs) [1.2.1, 1.3.2]. The most prominent isoforms in the gut are the L-type channels (Cav1.2 and Cav1.3) and the T-type channels (Cav3.2), which are responsible for electromechanical coupling and the generation of rhythmic contractions known as peristalsis [1.2.1, 1.3.2]. Dysregulation of these channels is associated with functional gastrointestinal disorders, including irritable bowel syndrome (IBS), chronic constipation, and diarrhea, as well as systemic conditions like Timothy syndrome, which can manifest as paralytic ileus [1.1.1, 1.3.2]. Pharmacological modulation of intestinal VGCCs is a mainstay in treating motility issues; calcium channel blockers (CCBs) such as nifedipine, verapamil, and gut-selective agents like pinaverium bromide act by inhibiting calcium influx to induce smooth muscle relaxation [1.4.1]. Additionally, gabapentinoids that target the auxiliary alpha2-delta subunits are utilized to manage visceral pain associated with these channels [1.4.3, 1.4.4]. However, the therapeutic use of systemic CCBs is often limited by safety concerns, including hypotension, peripheral edema, and paradoxical constipation, necessitating the development of more localized or isoform-specific treatments [1.4.1, 1.5.2].

Other names

Intestinal voltage-dependent calcium channelIntestinal VDCCGastrointestinal voltage-gated calcium channelCav1.2 (in the intestine)Cav1.3 (in the intestine)Cav3.2 (in the intestine)

Inhibition of calcium ion influx through voltage-gated channels in the gastrointestinal tract, leading to smooth muscle relaxation and reduced neuronal excitability.